GSK struck a deal to buy the rights to CureVac’s Covid-19 and flu vaccines for up to $1.56 billion, in a bid to regain ground lost to newcomers to the vaccine market during the pandemic.
Trending
- Michelangelo: The man, the brand, the mystery
- 'One Battle After Another' wins six BAFTA awards including best picture and director
- Britney Spears seen driving ‘erratically’ before arrest, say police | Ents & Arts News
- How We Analyzed the Strike on the Iranian School
- Iranian civilians seek shelter abroad
- Death toll mounts in Middle East war: Over 1,400 killed across Iran, Lebanon and Israel
- Why the US says India can buy Russian oil again
- Emirates resumes some Dubai flights – what's the latest on travel to UK?
